Pharmacy
Here's a look at what Mayo achieved and what goes into such an agreement with patients.
The antitrust concern over the Medicare prescription drug plans is holding up approval of the $69 billion deal.
PBMs have been dogged by controversy for years, and yet they've become a fixture -- which David Henka sees as a real problem.
It has funds for behavioral and mental health providers, for potential EHR incentives and for hospitals to better care for infants with neonatal abstinence syndrome.
The next expected approval is for CVS Health's $69 billion acquisition of Aetna.
Americans are dissatisfied with how both parties in Congress are handling the issue, with Democrats and Republicans faring almost equally poorly.
New CEO Martin VanTrieste will receive no pay and the startup will initially focus on 14 drugs.
The analysis, done for PhRMA, found that 320 hospitals marked up some medicine prices more than 1,000 percent.
It is the first study to examine financial conflict of interest in the publication of clinical trials that underpin FDA approval of new oncology drugs.
Majmudar's role within the company has yet to be announced, but he arrives from the Healthcare Transformation Lab.